PVRI 2026 Exhibitors & Sponsors
Collaboration drives everything we do. Our exhibitors and sponsors make PVRI 2026 possible — supporting global research, education, and innovation in PVD.
Thank you for helping us connect the world’s leading experts and advance care for people living with PH and related conditions. Together, we’re making a lasting impact.
Premium Sponsor: United Therapeutics
Thank you to United Therapeutics for sponsoring both Congress Luncheons: the Career Catalyst Luncheon - a leading mentorship event held on 30 January, & the Women in Pulmonary Hypertension Luncheon held on 31 January. Too often, certain voices are missing from leadership roles in medicine. Addressing this imbalance presents an opportunity to enhance learning, diversify decision-making, and foster innovation, ultimately improving patient care. The time for change is now. ‘INSPIRE PH’ is an initiative by United Therapeutics designed to support educational opportunities in PH and enhance professional networks, fostering a more inclusive and diverse community. We unite and amplify everyone’s voices to strengthen our shared interests.
At United Therapeutics, we partner with patients and healthcare providers to fight pulmonary hypertension and other lung diseases. Our research into promising pulmonary therapies has informed and shaped our long-term goal of an unlimited supply of transplantable organs. We are the first publicly traded biotechnology company organised to become a sustainable Public Benefit Corporation. We take our environmental, social, and governance responsibilities seriously, with core values that include safety, innovation, access, compliance, and ethics. Learn more at www.unither.com.
Premium Sponsor: Liquidia
Thank you to Liquidia for sponsoring the Networking Reception on 29 January - bringing together leading minds in PH for a wonderful evening of connection, collaboration and inspiration. Liquidia are also sponsoring the 'PH Associated with lung diseases: hope or hype?' session in the main programme on 30 January.
Liquidia Corporation is dedicated to the development and commercialization of best-in-class therapies with the potential to improve the standard of care for patients with rare cardiopulmonary diseases. We are difference makers driven to help patients with cardiopulmonary disease breathe easier and live longer. Each of us is committed to our mission to change patients’ lives for the better by enhancing drug delivery to the lungs and making every breath count.
Gold Sponsor: Interact Bio
Thank you to Interact Bio for sponsoring all 3 moderated poster sessions on 29, 30 and 31 January. In these cutting-edge sessions, attendees will cast their votes to choose the winning poster of the day. The winners will each receive a £200 cash award presented to the lead authors.
Interact Bio Ltd is a biotechnology company developing novel agents for the treatment of rare cardiovascular diseases. Our approach exploits cutting edge antibody discovery to inhibit or enhance cell signalling via genetically and clinically validated pathways for pulmonary arterial hypertension (PAH) and hereditary haemorrhagic telangiectasia (HHT). Interact Bio was founded in 2023 based on world-leading expertise in the pathobiology of PAH/HHT and is located in Cambridge, UK.
Gold Sponsor: Pulmovant
Thank you to Pulmovant for generously sponsoring the PVRI 2026 Congress lanyards — ensuring every delegate begins the meeting with your support quite literally in hand. This high-visibility contribution helps create a seamless congress experience for all attendees, while spotlighting Pulmovant’s ongoing dedication to innovation in pulmonary care.
Pulvomant is a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases and is a Roivant (Nasdaq: ROIV) company. Pulmovant’s first investigational candidate, mosliciguat, is designed to provide a novel, once-daily, inhaled treatment option for patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD). Mosliciguat is a potential first-in-class soluble guanylate cyclase activator with a differentiated mechanism of action currently being evaluated in the Phase 2 PHocus global clinical trial in PH-ILD. For more information, please visit www.pulmovant.com.
Silver Sponsor: Bayer
Thank you to Bayer for supporting seamless connectivity at PVRI 2026 as our exclusive Wi-Fi sponsor — enabling delegates to stay connected, access scientific content, and engage fully throughout the Congress. This essential contribution ensures our global community can collaborate effortlessly and make the most of every session.
Bayer’s Legacy in PH Innovation: Since 1997, Bayer has been at the forefront of pulmonary hypertension research—from pioneering inhaled iloprost (Ventavis) to developing the first-in-class sGC stimulator riociguat (Adempas). Our commitment to innovation continues, most marked by the recent Adempas’ pediatric approval in Europe—made possible through close collaboration with academia, patient organizations, regulators, and the PVRI.
Meet the PVRI 2026 Exhibitors
Our exhibitors are an essential part of PVRI 2026 — a vibrant hub of innovation, collaboration, and scientific discovery. Each organisation brings unique expertise to the global pulmonary hypertension community, helping to advance research, accelerate new therapies, and improve care for people living with PH and related PVDs worldwide.
We’re grateful to each of our exhibitors for their commitment to progress and for contributing to an environment where science, partnership, and purpose thrive.
Platinum Exhibitor: MSD
Location: Exhibition Hall - Stand 2
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
Platinum Exhibitor: Insmed
Location: Exhibition Hall - Stand 1
Insmed is a biopharmaceutical company, located in Bridgewater NJ, driven by a mission to transform the lives of patients with serious and rare diseases. Guided by its vision to be a globally recognised leader in biotechnology, Insmed is dedicated to empowering great people to deliver life-altering therapies with urgency, compassion, and scientific excellence. Insmed is advancing science through its rich pipeline in the areas of Rare Pulmonary Diseases, Genetic Diseases, neutrophil-Driven Inflammatory Conditions, Mycobacterium avium complex (MAC) Lung Disease and Pre-Clinical Research.
More information can be found on their website at Insmed.com
Gold Exhibitor: Gossamer Bio
Location: Exhibition Hall - Stand 4
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to enhance the lives of people living with these rare diseases.
The name Gossamer Bio depicts the symbolism behind the gossamer thread, the fragile connection that binds all relationships in life. In our context, this is intended to highlight the importance of our relationships with patients, employees, shareholders, providers, and partners. We take these relationships seriously and aim to strengthen these connections continuously.
Gold Exhibitor: Liquidia
Location: Exhibition Hall - Stand 3
Liquidia Corporation is dedicated to the development and commercialization of best-in-class therapies with the potential to improve the standard of care for patients with rare cardiopulmonary diseases. We are difference makers driven to help patients with cardiopulmonary disease breathe easier and live longer. Each of us is committed to our mission to change patients’ lives for the better by enhancing drug delivery to the lungs and making every breath count.
Alliance for PH
The Alliance for Pulmonary Hypertension, founded in Brussels in 2020, has as its mission to empower patients through knowledge-sharing. Our centralized repository of 800+ resources, news updates, live webinars, and educational programs give patients and families the tools to make informed decisions, advocate effectively, and lead fulfilling lives.
There’s still time to exhibit or sponsor PVRI 2026 Dublin.
Join us in bringing together global PH experts, driving collaboration, and shaping the future of pulmonary vascular research. Explore how your organisation can get involved.
SPONSORSHIP
Our next annual global congress, PVRI 2027, is on course to be an influential gathering of leading and early career researchers, clinicians, and industry experts dedicated to addressing the complexities of PH worldwide.
